Search

Displaying results 3171 - 3180 of 4437 in total
  1. Drug

    Agatolimod

    go.drugbank.com/drugs/DB15018
    Investigational

    Agatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).

  2. Drug

    XT-150

    go.drugbank.com/drugs/DB21756
    Investigational

    [L52125] It is being developed by Xalud Therapeutics.

  3. Drug

    Pranlukast

    go.drugbank.com/drugs/DB01411
    Investigational

    It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

  4. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform.

  5. Drug

    Doramectin

    go.drugbank.com/drugs/DB11400
    ExperimentalVet approved

    Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites

  6. Drug

    Boron

    go.drugbank.com/drugs/DB11203
    ApprovedInvestigational

    Natural boron exists in 2 stable isotopes however pure boron is hard to prepare due to contamination by different elements.

  7. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  8. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence

  9. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.

  10. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.